1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Summary of antiplatelet therapy
Stable Progression % Progression
AS (+), n = 62 46 16 25.8
AS (−), n = 33 28 5 15.2
TI (+), n = 26 14 12 46.2
TI (−), n = 69 60 9 13.0
CL (+), n = 26 23 3 11.5
CL (−), n = 69 51 18 26.1
CIL (+), n = 29 27 2 6.9
CIL (−), n = 66 47 19 28.8
Note:—The progression of carotid artery stenosis was significantly less in patients with cilostazol use compared with patients without cilostazol use (P = .03). AS indicates aspirin; TI, ticlopidine; CL, clopidogrel; CIL, cilostazol. Forty-seven patients received single antiplatelet therapy (AS 16, TI 5, CL 14, CIL 12), 48 patients received dual antiplatelet therapy (AS+TI 20, AS+CL 11, AS+CIL 15, TI+CIL 1, CL+CIL 1). The progression of carotid artery stenosis was significantly less in patients with cilostazol use compared with patients without cilostazol use (P = .03).